Buyback yield (TTM)
0.08%
Shareholder yield (TTM)
4.17%
5Y share count change
-9.6%
Buyback spend (TTM)
$98.00M
Cumulative buybacks
$47.68B
Key takeaways
- Bristol-Myers Squibb (BMY) repurchased about $98.00M of stock over the trailing twelve months.
- Diluted share count is down 9.6% over the last ~5 fiscal years — buybacks are net-shrinking the share base.
- TTM buyback ÷ stock-based-comp ratio of 0.18× — repurchases only partially offset SBC dilution.
- Cash buyback spend has compounded at -100.0% per year over the latest 5-year window.
- TTM repurchases used about 1% of free cash flow remaining after dividends.
Dividend & buyback yield over time for Bristol-Myers Squibb (BMY)
Stacked annual yields — buyback yield (TTM cash repurchases ÷ market cap) plus dividend yield from the same fiscal-year-end key-metrics period — show how total cash return per dollar of equity has evolved.
Diluted vs basic shares (annual) for Bristol-Myers Squibb (BMY)
Diluted weighted-average shares are the EPS denominator — a falling count means buybacks are outpacing SBC dilution.
Year-over-year change in diluted shares for Bristol-Myers Squibb (BMY)
Green is fewer shares vs the prior fiscal year (net repurchase); red is growth (dilution). The earliest year shown has no prior year to compare.
Cash buyback spend over time for Bristol-Myers Squibb (BMY)
Latest: $0.00
Overview
As of the 2025 fiscal year, Bristol-Myers Squibb (BMY) reported buyback spend of $0.00.
Through 2020–2025 (5 years), Bristol-Myers Squibb buyback spend delivered a -100.0% annualised rate; with a net decline across the window.
Bristol-Myers Squibb buyback spend peaked at $8.00B in 2022; the latest annual figure is $0.00 in 2025 (100.0% below peak).
The highest annual buyback spend of $8.00B was reported in 2022. The lowest in the available history was $0.00 in 2003.
Bristol-Myers Squibb Buyback Spend 2025: $0.00
Bristol-Myers Squibb buyback spend in 2025 was $0.00.
Bristol-Myers Squibb Buyback Spend 2024: $0.00
Bristol-Myers Squibb buyback spend in 2024 was $0.00, plunged 100.0% below 2023.
Bristol-Myers Squibb Buyback Spend 2023: $5.16B
2023's buyback spend for Bristol-Myers Squibb came in at $5.16B, plunged 35.6% below 2022.
Bristol-Myers Squibb Buyback Spend 2022: $8.00B
Bristol-Myers Squibb posted buyback spend of $8.00B in 2022, grew 27.3% from 2021. This figure represents the highest annual value in the available history.
Bristol-Myers Squibb Buyback Spend 2021: $6.29B
Bristol-Myers Squibb buyback spend in 2021 was $6.29B.
See more financial history for Bristol-Myers Squibb (BMY).
Buyback, SBC & dilution history
Buyback spend, SBC, net dilution effect, and share count.
| 2025 | $0.00 | $553.00M | −$553.00M | — | 2.04B | +0.7% | |
| 2024 | $0.00 | $507.00M | −$507.00M | — | 2.03B | -2.5% | |
| 2023 | $5.16B | $518.00M | $4.64B | 4.96% | 2.08B | -3.2% | |
| 2022 | $8.00B | $457.00M | $7.54B | 5.28% | 2.15B | -4.4% | |
| 2021 | $6.29B | $583.00M | $5.70B | 4.68% | 2.25B | -0.6% | |
| 2020 | $1.55B | $779.00M | $767.00M | 1.11% | 2.26B | +31.9% | |
| 2019 | $7.30B | $441.00M | $6.86B | 5.94% | 1.71B | +4.6% | |
| 2018 | $320.00M | $221.00M | $99.00M | 0.38% | 1.64B | -0.9% | |
| 2017 | $2.47B | $199.00M | $2.27B | 2.46% | 1.65B | -1.7% | |
| 2016 | $231.00M | $205.00M | $26.00M | 0.24% | 1.68B | +0.1% | |
| 2015 | $0.00 | $235.00M | −$235.00M | — | 1.68B | +0.5% | |
| 2014 | $0.00 | $213.00M | −$213.00M | — | 1.67B | +0.5% | |
| 2013 | $433.00M | $191.00M | $242.00M | 0.49% | 1.66B | -1.5% | |
| 2012 | $2.40B | $154.00M | $2.25B | 4.49% | 1.69B | -1.7% | |
| 2011 | $1.22B | $161.00M | $1.06B | 2.05% | 1.72B | -0.6% | |
| 2010 | $576.00M | $193.00M | $383.00M | 1.27% | 1.73B | -12.7% | |
| 2009 | $0.00 | $183.00M | −$183.00M | — | 1.98B | -1.1% | |
| 2008 | $0.00 | $181.00M | −$181.00M | — | 2.00B | +1.1% | |
| 2007 | $0.00 | $0.00 | $0.00 | — | 1.98B | +0.9% | |
| 2006 | $0.00 | $0.00 | $0.00 | — | 1.96B | -1.0% | |
| 2005 | $0.00 | $0.00 | $0.00 | — | 1.98B | +0.4% | |
| 2004 | $0.00 | $0.00 | $0.00 | — | 1.98B | +1.3% | |
| 2003 | $0.00 | $0.00 | $0.00 | — | 1.95B | -3.3% | |
| 2002 | $164.00M | $0.00 | $164.00M | 0.32% | 2.02B | +2.6% | |
| 2001 | $1.59B | $0.00 | $1.59B | 1.61% | 1.97B | -1.6% | |
| 2000 | $2.34B | $0.00 | $2.34B | — | 2.00B | -1.5% | |
| 1999 | $1.42B | $0.00 | $1.42B | — | 2.03B | -0.2% | |
| 1998 | $1.56B | $0.00 | $1.56B | — | 2.03B | -0.5% | |
| 1997 | $1.16B | $0.00 | $1.16B | — | 2.04B | +0.3% | |
| 1996 | $852.00M | $0.00 | $852.00M | — | 2.04B | — | |
| 1995 | $244.00M | $0.00 | $244.00M | — | — | — | |
| 1994 | $701.00M | $0.00 | $701.00M | — | — | — | |
| 1993 | $419.00M | $0.00 | $419.00M | — | — | — | |
| 1992 | $228.00M | $0.00 | $228.00M | — | — | — | |
| 1991 | $447.00M | $0.00 | $447.00M | — | — | — | |
| 1990 | $562.00M | $0.00 | $562.00M | — | — | — | |
| 1989 | $51.00M | $0.00 | $51.00M | — | — | — |
- 2025$0.00
- 2024$0.00
- 2023$5.16B
- 2022$8.00B
- 2021$6.29B
- 2020$1.55B
- 2019$7.30B
- 2018$320.00M
- 2017$2.47B
- 2016$231.00M
- 2015$0.00
- 2014$0.00
- 2013$433.00M
- 2012$2.40B
- 2011$1.22B
- 2010$576.00M
- 2009$0.00
- 2008$0.00
- 2007$0.00
- 2006$0.00
- 2005$0.00
- 2004$0.00
- 2003$0.00
- 2002$164.00M
- 2001$1.59B
- 2000$2.34B
- 1999$1.42B
- 1998$1.56B
- 1997$1.16B
- 1996$852.00M
- 1995$244.00M
- 1994$701.00M
- 1993$419.00M
- 1992$228.00M
- 1991$447.00M
- 1990$562.00M
- 1989$51.00M
Buybacks vs stock-based compensation for Bristol-Myers Squibb (BMY)
Annual cash repurchases set against stock-based compensation. Coverage above 1× means buybacks fully offset the equity dilution from SBC. TTM coverage: 0.18×.
Buybacks vs dividends (share of cash returned) for Bristol-Myers Squibb (BMY)
How Bristol-Myers Squibb splits cash returned to shareholders between dividends and buybacks.
Sector peers by buyback spend
Companies in the same sector as Bristol-Myers Squibb, ranked by their latest buyback spend.
| $5.95B | |
| $5.54B | |
| $5.08B | |
| $4.11B | |
| $980.00M | |
| $216.35M | |
| $0.00 | |
| $0.00 |
- $5.95B
- $5.54B
- $5.08B
- $4.11B
- $980.00M
- $216.35M
- $0.00
- $0.00
Buyback capacity (TTM)
Free cash flow minus dividends paid versus actual TTM repurchases — the headroom bar shows how much of post-dividend FCF is still being deployed elsewhere.
Headroom $6.84B (TTM FCF − TTM dividends, clamped at zero).
Frequently asked questions
Data & methodology
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation